Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Vienna Insurance Group (18/05/2020)

24.05.2020

Vienna Insurance Group: Vienna Insurance Group has invested in Austrian biotech company Apeiron Biologics AG, which is currently working on a drug to treat COVID-19. Josef Penninger was involved in the development of the medication, which is being administered to a group of COVID-19 patients as part of a pan-European clinical trial. Due to the COVID-19 pandemic, the company is currently focusing on developing a drug to combat the disease. By collaborating with Apeiron, VIG-Group is aiming to play its part in the fight against COVID-19, which in turn will enable it to live up to its social responsibilities as a good corporate citizen. “As an insurer, our most fundamental task is to protect people against risks. In the current situation, health has become the focus of attention, and as a provider of life and health insurance, playing a part in safeguarding health and also in the prevention of diseases is one of our leading priorities. Our investment in Apeiron is a meaningful, long-term option that enables us to bring to life our promise of ‘protecting what matters’, while also keeping our economic goals in mind,” commented General Manager Elisabeth Stadler. Under its Agenda 2020 management programme, the Group has already implemented measures aimed at promoting health and well-being, and is stepping up its operations in the health insurance segment. The acquisition of a stake in Apeiron in the course of a capital increase is in line with this thrust, and dovetails seamlessly with the Group’s overarching strategy.
VIG: weekly performance: 0.67%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/05/2020)


Partners









latest 21st Austria

21st Austria weekly - Vienna Insurance Group (18/05/2020)


24.05.2020


Vienna Insurance Group: Vienna Insurance Group has invested in Austrian biotech company Apeiron Biologics AG, which is currently working on a drug to treat COVID-19. Josef Penninger was involved in the development of the medication, which is being administered to a group of COVID-19 patients as part of a pan-European clinical trial. Due to the COVID-19 pandemic, the company is currently focusing on developing a drug to combat the disease. By collaborating with Apeiron, VIG-Group is aiming to play its part in the fight against COVID-19, which in turn will enable it to live up to its social responsibilities as a good corporate citizen. “As an insurer, our most fundamental task is to protect people against risks. In the current situation, health has become the focus of attention, and as a provider of life and health insurance, playing a part in safeguarding health and also in the prevention of diseases is one of our leading priorities. Our investment in Apeiron is a meaningful, long-term option that enables us to bring to life our promise of ‘protecting what matters’, while also keeping our economic goals in mind,” commented General Manager Elisabeth Stadler. Under its Agenda 2020 management programme, the Group has already implemented measures aimed at promoting health and well-being, and is stepping up its operations in the health insurance segment. The acquisition of a stake in Apeiron in the course of a capital increase is in line with this thrust, and dovetails seamlessly with the Group’s overarching strategy.
VIG: weekly performance: 0.67%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/05/2020)




 

Bildnachweis

Aktien auf dem Radar:Semperit, Frequentis, Österreichische Post, Warimpex, Agrana, Polytec, Rosgix, Wienerberger, FACC, Palfinger, Rosenbauer, Wolford.


Random Partner

VIG
Die Vienna Insurance Group (VIG) ist mit rund 50 Konzerngesellschaften und über 24.000 Mitarbeitern in 25 Ländern aktiv. Bereits seit 1994 notiert die VIG an der Wiener Börse und zählt heute zu den Top-Unternehmen im Segment “prime market“ und weist eine attraktive Dividendenpolitik auf.

>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten